ArticleCureus2025
Lost in Cognition: Paraneoplastic Rhombencephalitis With Anti-Ri/Antineuronal Nuclear Antibody Type 2 (ANNA-2) Antibodies Presenting as Rapid-Onset Cognitive Decline and Ophthalmoplegia-Ataxia With Reversible Brainstem Lesion.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anti-Ri/antineuronal nuclear antibody type 2 (ANNA-2) autoantibodies have emerged as significant markers within the realm of paraneoplastic neurological syndromes (PNS), which are recognized for their connection with onconeural antibodies and their potential to cause neurological manifestations in the presence of an underlying malignancy. If left untreated, PNS involving anti-Ri antibodies can result in substantial morbidity and mortality, and the heterogeneous range of associated syndromes and clinical presentations often complicates the diagnosis. We report the case of a 67-year-old Asian female patient with a history of hypertension and diabetes mellitus who developed progressive gait ataxia, diplopia, dysphagia, facial twitching, and cognitive decline over three months. Neurological examination revealed conjugate horizontal gaze palsy, partial ptosis, oromandibular dystonia, hyperreflexia, and ataxia. Brain magnetic resonance imaging (MRI) showed non-enhancing T2/fluid-attenuated inversion recovery (FLAIR) patchy signal changes in the brainstem, and cerebrospinal fluid (CSF) analysis revealed mildly elevated protein and pleocytosis. ANNA-2 antibodies were positive in both serum and CSF, prompting a malignancy workup that uncovered an invasive, poorly differentiated ductal carcinoma of the breast. The patient was started on high-dose corticosteroids, resulting in partial radiological and clinical improvement. In conclusion, a subacute gait ataxia, ophthalmoparesis, and jaw dystonia should raise suspicion for anti-Ri/ANNA-2 rhombencephalitis, warranting prompt malignancy evaluation and early immunotherapy to optimize outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.